---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-090170"
form_type: "8-K"
ticker: "CRSP"
cik: "0001674416"
company_name: "CRISPR Therapeutics AG"
filed_at: "2025-06-26T23:59:59+00:00"
generated_at: "2026-05-18T17:58:36.202450+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CRISPR Therapeutics reports up to 86% LDL reduction with CTX310; delays CTX320 data to H1 2026

## Summary
- CTX310 Phase 1 shows up to 82% TG and 86% LDL reductions at 0.8 mg/kg with stable liver enzymes.
- CTX320 (LPA gene) Phase 1 data update expected in first half of 2026 due to strategic pause for Lp(a) landscape insights.
- CTX340 (AGT gene) for refractory hypertension advancing through IND/CTA-enabling studies.
- CTX310 trial enrolling HoFH, severe hypertriglyceridemia, HeFH, and mixed dyslipidemia patients.

## SEC filing metadata
- accession: 0000950170-25-090170
- form_type: 8-K
- ticker: CRSP
- cik: 0001674416
- company_name: CRISPR Therapeutics AG
- filed_at: 2025-06-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674416/000095017025090170/0000950170-25-090170-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674416/000095017025090170/crsp-20250626.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-090170
- JSON: https://secwatch.observer/filing/0000950170-25-090170.json
- Plain text: https://secwatch.observer/filing/0000950170-25-090170.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.